ERBB2 and breast cancer: Similarly, PKM2 overexpression was observed in tissue samples of various breast cancer subtypes, including TNBC, luminal, and HER2-positive cancers, significantly associated with poor prognosis, EMT and increased chemosensitivity to epirubicin and 5-fluorouracil [89,90].